C5a-induced aortic contraction: Effect of an antihistamine and inhibitors of arachidonate metabolism

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cleavage of the complement protein C5 by activation of the complement system yields a low molecular weight fragment, C5a, historically referred to as anaphylatoxin. Among the biological activities of C5a is the ability to contract isolated smooth muscle. This report is concerned with initial studies identifying mediators resonsible for C5a-induced contraction of isolated guinea-pig aortic rings. C5a, purified from yeast-activated guinea-pig serum, caused a concentration-related contraction of the isolated guinea-pig aorta. The H1 antagonist diphenhydramine partially inhibited the response of the aorta to C5a, indicating that released histamine was, at least in part, responsible for the contraction. 5,8,11,14-Eicosatetraynoate, an inhibitor of both the lipoxygenase and cyclooxygenase pathway of arachidonate metabolism, inhibited the C5a-induced aortic contraction to an even greater extent than diphenhydramine, suggesting that products of arachidonate metabolism also play a role in the contraction. The cyclooxygenase inhibitors aspirin and indomethacin did not inhibit the C5a-induced aortic contraction, yet a combination of aspirin and diphenhydramine or indomethacin and diphenhydramine completely inhibited the aortic response to C5a. The presence of aspirin did not affect aortic response to C5a. The presence of aspirin did not affect the ability of diphenhydramine to inhibit the response of the aorta to exogenous histamine, thus suggesting that cyclooxygenase products were not affecting the reactivity of histamine at the target smooth muscle. These studies indicate that both histamine and cyclooxygenase products are mediators responsible for C5a-induced aortic contraction.

Original languageEnglish (US)
Pages (from-to)102-107
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume220
Issue number1
StatePublished - Jan 1 1982

Fingerprint

Diphenhydramine
Histamine Antagonists
Histamine
Aspirin
Aorta
Guinea Pigs
Cyclooxygenase Inhibitors
Prostaglandin-Endoperoxide Synthases
Indomethacin
Smooth Muscle
Complement C5
Anaphylatoxins
Lipoxygenase Inhibitors
Complement Activation
Complement System Proteins
Yeasts
Molecular Weight
Serum

Cite this

@article{b85cfc1250bf4d25bc7145257f8a0459,
title = "C5a-induced aortic contraction: Effect of an antihistamine and inhibitors of arachidonate metabolism",
abstract = "Cleavage of the complement protein C5 by activation of the complement system yields a low molecular weight fragment, C5a, historically referred to as anaphylatoxin. Among the biological activities of C5a is the ability to contract isolated smooth muscle. This report is concerned with initial studies identifying mediators resonsible for C5a-induced contraction of isolated guinea-pig aortic rings. C5a, purified from yeast-activated guinea-pig serum, caused a concentration-related contraction of the isolated guinea-pig aorta. The H1 antagonist diphenhydramine partially inhibited the response of the aorta to C5a, indicating that released histamine was, at least in part, responsible for the contraction. 5,8,11,14-Eicosatetraynoate, an inhibitor of both the lipoxygenase and cyclooxygenase pathway of arachidonate metabolism, inhibited the C5a-induced aortic contraction to an even greater extent than diphenhydramine, suggesting that products of arachidonate metabolism also play a role in the contraction. The cyclooxygenase inhibitors aspirin and indomethacin did not inhibit the C5a-induced aortic contraction, yet a combination of aspirin and diphenhydramine or indomethacin and diphenhydramine completely inhibited the aortic response to C5a. The presence of aspirin did not affect aortic response to C5a. The presence of aspirin did not affect the ability of diphenhydramine to inhibit the response of the aorta to exogenous histamine, thus suggesting that cyclooxygenase products were not affecting the reactivity of histamine at the target smooth muscle. These studies indicate that both histamine and cyclooxygenase products are mediators responsible for C5a-induced aortic contraction.",
author = "Regal, {J. F.}",
year = "1982",
month = "1",
day = "1",
language = "English (US)",
volume = "220",
pages = "102--107",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - C5a-induced aortic contraction

T2 - Effect of an antihistamine and inhibitors of arachidonate metabolism

AU - Regal, J. F.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Cleavage of the complement protein C5 by activation of the complement system yields a low molecular weight fragment, C5a, historically referred to as anaphylatoxin. Among the biological activities of C5a is the ability to contract isolated smooth muscle. This report is concerned with initial studies identifying mediators resonsible for C5a-induced contraction of isolated guinea-pig aortic rings. C5a, purified from yeast-activated guinea-pig serum, caused a concentration-related contraction of the isolated guinea-pig aorta. The H1 antagonist diphenhydramine partially inhibited the response of the aorta to C5a, indicating that released histamine was, at least in part, responsible for the contraction. 5,8,11,14-Eicosatetraynoate, an inhibitor of both the lipoxygenase and cyclooxygenase pathway of arachidonate metabolism, inhibited the C5a-induced aortic contraction to an even greater extent than diphenhydramine, suggesting that products of arachidonate metabolism also play a role in the contraction. The cyclooxygenase inhibitors aspirin and indomethacin did not inhibit the C5a-induced aortic contraction, yet a combination of aspirin and diphenhydramine or indomethacin and diphenhydramine completely inhibited the aortic response to C5a. The presence of aspirin did not affect aortic response to C5a. The presence of aspirin did not affect the ability of diphenhydramine to inhibit the response of the aorta to exogenous histamine, thus suggesting that cyclooxygenase products were not affecting the reactivity of histamine at the target smooth muscle. These studies indicate that both histamine and cyclooxygenase products are mediators responsible for C5a-induced aortic contraction.

AB - Cleavage of the complement protein C5 by activation of the complement system yields a low molecular weight fragment, C5a, historically referred to as anaphylatoxin. Among the biological activities of C5a is the ability to contract isolated smooth muscle. This report is concerned with initial studies identifying mediators resonsible for C5a-induced contraction of isolated guinea-pig aortic rings. C5a, purified from yeast-activated guinea-pig serum, caused a concentration-related contraction of the isolated guinea-pig aorta. The H1 antagonist diphenhydramine partially inhibited the response of the aorta to C5a, indicating that released histamine was, at least in part, responsible for the contraction. 5,8,11,14-Eicosatetraynoate, an inhibitor of both the lipoxygenase and cyclooxygenase pathway of arachidonate metabolism, inhibited the C5a-induced aortic contraction to an even greater extent than diphenhydramine, suggesting that products of arachidonate metabolism also play a role in the contraction. The cyclooxygenase inhibitors aspirin and indomethacin did not inhibit the C5a-induced aortic contraction, yet a combination of aspirin and diphenhydramine or indomethacin and diphenhydramine completely inhibited the aortic response to C5a. The presence of aspirin did not affect aortic response to C5a. The presence of aspirin did not affect the ability of diphenhydramine to inhibit the response of the aorta to exogenous histamine, thus suggesting that cyclooxygenase products were not affecting the reactivity of histamine at the target smooth muscle. These studies indicate that both histamine and cyclooxygenase products are mediators responsible for C5a-induced aortic contraction.

UR - http://www.scopus.com/inward/record.url?scp=0020052610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020052610&partnerID=8YFLogxK

M3 - Article

C2 - 6118427

AN - SCOPUS:0020052610

VL - 220

SP - 102

EP - 107

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -